The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Authors

  • Stefano Fagiuoli Gastroenterology, Hepatology and Transplantation Unit, Department of Medicine, Papa Giovanni XXIII Hospital, Bergamo - Italy
  • Matteo Ruggeri National Center for HTA, Istituto Superiore di Sanità, Rome and St. Camillus International University of Health and Medical Sciences, Rome - Italy
  • Filipa Aragao Maple Health Group, LLC, New York - US and NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon - Portugal
  • Rob Blissett Maple Health Group, LLC, New York - USA

DOI:

https://doi.org/10.33393/grhta.2021.2183

Keywords:

Cost, Hepatitis C virus, Liver disease, Retention, Simplification

Abstract

Introduction: The current paradigm (CP) of hepatitis C virus (HCV) diagnosis and treatment in Italy’s National Health Service system has numerous steps. The European Association for the Study of the Liver recommends initiation of a pan-genotypic direct-acting antiviral regimen after a simple diagnostic process. The present study estimated the efficiency gains resulting from two simplified pathways from diagnosis to treatment of chronic hepatitis C patients in Italy over the next 5 years from a societal perspective.

Methods: The CP, a New Paradigm 1 (NP1), and a New Paradigm 2 (NP2) were evaluated in a Markov model. The NP1 model simplifies monitoring and laboratory test requirements in the diagnosis and treatment phases. The NP2 model also eliminates the primary care referral requirement.

Results: Treatment process time for non-cirrhotic patients was 48, 43, and 25 weeks in the CP, NP1, and NP2, respectively, and in cirrhotic patients was 49, 46, and 37 weeks. Under the CP, 19% of patients/year would be lost to follow-up, which decreases by 11% in NP1 and 100% in NP2. Compared with the CP, implementation of NP1 at 5 years would reduce compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liverrelated deaths by 12.6%, 12.4%, 8.1%, and 8.8%, respectively; these cases would be reduced by 94.0%, 93.8%, 61.0%, and 58.4% in NP2. Total 5-year costs with the CP, NP1, and NP2 are estimated at 135.6€ million, 110.5€ million, and 80.5€ million, respectively.

Conclusions: Simplification of HCV diagnosis and monitoring requirements would allow Italy to move closer to international guidelines with significant health benefits and economic gains.

References

Blach S, Zeuzem S, Manns M, et al; Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176. https://doi.org/10.1016/S2468-1253(16)30181-9 PMID:28404132

Gardini I, Bartoli M, Conforti M, Mennini FS, Marcellusi A. Estimation of the number of HCV-positive patients in Italy. PLoS One. 2019;14(10):e0223668. https://doi.org/10.1371/journal.pone.0223668 PMID:31671120

Dibonaventura MD, Yuan Y, Lescrauwaet B, et al. Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey. PLoS One 2014;9(1):e86070-e.

EASL Recommendations on Treatment of Hepatitis C. J Hepatology. 2018 [cited 2020 March 18]. Available from: https://easl.eu/publication/easl-recommendations-treatment-of-hepatitis-c/. (Accessed March 31, 2021)

Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Geneva, Switzerland: World Health Organization; 2016.

Web activation and publication of HCV register monitoring cards—policy update. Italian Medicines Agency; 2019 [cited 2020 March 23 ]. Available from:https://www.aifa.gov.it/-/attivazione-web-e-pubblicazione-schede-di-monitoraggio-registri-hcv-aggiornamento-criteri. (Accessed March 31, 2021)

Portuguese national program for viral hepatitis, 2017 report. Portuguese Ministry of Health; 2017 [cited 2020 March 23]. Available from: http://www.emcdda.europa.eu/drugs-library/programa-nacional-para-hepatites-virais_it. (Accessed March 31, 2021)

Puoti M. HCV/HIV coinfection: What is learned from PITER and cohort studies. Available at: https://www.progettopiter.it/Repository/News/PITER_Meeting_2019-05-07_Puoti_M.pdf. The PITER Meeting; Rome, Italy, 2019. (Accessed March 31, 2021)

Wiessing L, Ferri M, Grady B, et al; EMCDDA DRID group. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9(7):e103345. https://doi.org/10.1371/journal.pone.0103345 PMID:25068274

Chen Q, Ayer T, Bethea E, et al. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9(6):e026726. https://doi.org/10.1136/bmjopen-2018-026726 PMID:31189677

Cenderello G, Artioli S, Viscoli C, et al. Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. Clinicoecon Outcomes Res. 2015;8:15-21. https://doi.org/10.2147/CEOR.S93641PMID:26770065

Data update: Registries AIFA DAAs—chronic hepatitis C: Agenzia Italiana del Farmaco; 2019 [cited 2020 March 18]. Available from: https://www.aifa.gov.it/documents/20142/847506/Aggiornamento_dati_Registri_AIFA_DAAs-21-10-2019.pdf/4669322f-1ad4-40f9-8750-3f16742f1586. (Accessed March 31, 2021)

Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-431. https://doi.org/10.1002/hep.22375 PMID:18563841

Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979-1991. https://doi.org/10.1097/QAD.0b013e32830e6d51 PMID:18784461

Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res. 2019;20(3):251-257. https://doi.org/10.1080/14737167.2019.1629291 PMID:31204882

Ruggeri M, Romano F, Basile M, et al. Cost-effectiveness analysis of early treatment of chronic HCV with sofosbuvir/velpatasvir in Italy. Appl Health Econ Health Policy. 2018;16(5):711-722. https://doi.org/10.1007/s40258-018-0410-x PMID:30039348

Buggisch P, Wursthorn K, Stoehr A, et al. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS One. 2019;14(4):e0214795. https://doi.org/10.1371/journal.pone.0214795PMID:30946776

Degasperi E, Spinetti A, Lombardi A, et al; NAVIGATORE-Lombardia and Veneto Study Groups. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019;71(6):1106-1115. https://doi.org/10.1016/j.jhep.2019.07.020 PMID:31433303

Mangia A, Piazzolla V, Giannelli A, et al. SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. PLoS One. 2019;14(5):e0215783. https://doi.org/10.1371/journal.pone.0215783PMID:31091254

Mangia A, Milligan S, Khalili M, et al. GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: integrated analysis of 12 clinical practice cohorts. J Hepatol. 2019;70(1):e2-e3. https://doi.org/10.1016/S0618-8278(19)30003-9

Soria A, Lapadula G, Colella E, et al. THU-180-Treatment of genotype 3 HCV infection in the large real-life “Navigatore Lombardia” multicentre cohort: results from three different regimens. J Hepatol. 2019;70(1):e241. https://doi.org/10.1016/S0618-8278(19)30455-4

Christensen S, Ingiliz P, Mauss S, et al. Do resistance associated substitutions (RAS) or Ribavirin (RBV) use influence treatment success of Sofosbuvir (SOV)/Velpatasvir (VEL) in chronic hepatitis C genotype 3 (GT 3) infection?—Results from the GErman hepatitis C COhort (GECCO). Hepatology. 2017;66(suppl 1):36A.

Fagiuoli S, Agarwal K, Mangia A, et al. Effectiveness of sofosbuvir/velpatasvir for 12 weeks in HCV genotype 3 patients with compensated cirrhosis in clinical practice cohorts from around the world. Hepatology. 2018;68(suppl 1):360A.

Remuneration of hospital care for acute care, post-acute hospitalization of rehabilitation and long-term care and specialist outpatient care. 2012 [cited 2020 March 19]. Available from: https://www.gazzettaufficiale.it/eli/id/2013/01/28/13A00528/sg. (Accessed March 31, 2021)

Healthcare Fund for Commercial Company Executives: Tariff Nomenclator 2020. 2020 [cited 2020 March 19]. Available from: https://www.fasdac.it/public/Contenuto/0_nomenclatore_tariffario_Fasdac_2020_agg._01-07-2020.pdf (Accessed March 31, 2021)

Ruggeri M, Coretti S, Romano F, Kondili LA, Vella S, Cicchetti A. Economic evaluation of the hepatitis c virus treatment extension to early-stage fibrosis patients: evidence from the PITER real-world cohort. Value Health. 2018;21(7):783-791. https://doi.org/10.1016/j.jval.2017.10.021 PMID:30005750

Purchasing power parities. 2019 [cited 2020 March 20]. Available from: https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm. (Accessed March 31, 2021)

Moussalli J, Delaquaize H, Boubilley D, et al. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract. 2010;2010:261472.

Additional Files

Published

2021-04-15

How to Cite

1.
Fagiuoli S, Ruggeri M, Aragao F, Blissett R. The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment. Grhta [Internet]. 2021 Apr. 15 [cited 2021 Oct. 24];8:58-66. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2183

Issue

Section

Original Research Article

Most read articles by the same author(s)